Therapeutic Approach

Archive: January, 2012

Ritter Pharmaceuticals’ RP-G28 Improves Lactose Intolerance Symptoms and Lactose Digestion in Phase 2 Trial

LOS ANGELES, CALIFORNIA, January 5, 2012–Ritter Pharmaceuticals, Inc. today announced positive results from its Phase 2 study of RP-G28, the first-in-class treatment of lactose intolerance. Treatment with RP-G28 was shown to improve digestive symptoms associated with lactose intolerance, including abdominal pain. Importantly, the reduction of breath hydrogen production after a lactose load was measured, providing […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD